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Abstract. Background: Cancer treatment often fails due to
multidrug resistance (MDR) of the tumor cells. One of the major
causes is overexpression of P-glycoprotein (P-gp). Materials and
Methods: By N-substitution reactions of diamine, amino acid and
amino alcohol derivatives with 1-substituted tetrahydroisoquinoline
skeleton, structurally diverse 1,2-disubstituted 1,2,3,4-
tetrahydroisoquinolines were synthesized. The compounds were
assayed as P-gp inhibitors using a standard functional assay with
rhodamine (6G) on MCF-7/Adr cells. Cytotoxicity was investigated
on HeLa cells using an antiproliferative assay. Results: Five of the
24 compounds showed greater P-gp inhibition than the control
compound verapamil with AC50 values (concentration of the
compound eliciting 50% of the maximal rhodamine 6G
accumulation) significantly lower than that of verapamil.
Conclusion: Novel compounds were synthesized that showed
MDR-reversal effect. One of them, (1’R*,2R*)-2-{2’-[2"-hydroxy-
3"-(·-naphthyloxy)propyl]-6’,7’-dimethoxy-1’,2’,3’,4’-tetrahydro-1’-
isoquinolyl}propan-1-ol hydrochloride, showed two times higher
efficacy than verapamil at 10 times lower concentrations. The
outcome makes this molecule an attractive subject for further
investigation and development.
The successful treatment of metastatic cancer often fails due
to the development of multidrug resistance (MDR) of the
tumor cells. Multidrug-resistant tumors show cross-resistance
to many classes of chemotherapeutic agents that were never
part of their treatment. One of the major mechanisms
underlying MDR consists of the overexpression of a plasma
membrane-bound protein (P-gp) (1,2). This mdr1 gene
product extrudes antitumor agents out of the cells, thereby
reducing their intracellular accumulation and therefore their
efficacy. Studies have demonstrated that a wide range of
structurally and functionally unrelated compounds (e.g.
calcium channel blockers, calmodulin inhibitors, coronary
vasodilators, antimalarial agents, cyclosporines), are able to
reverse MDR by modulation of P-gp or MRP1 (multidrug
resistance protein). However, since these first generation
MDR inhibitors are active only at high concentrations, they
proved to be of limited relevance for clinical practice. Due to
the great therapeutic importance, in recent years enormous
efforts have been made to find new natural compounds or
synthetic compounds with MDR reversal activity (3-11). Some
second (e.g. valspodar, biricodar) and third generation
compounds (e.g. tariquidar, zosuquidar) have been developed
which are in different phases of clinical trials (12-14).
The structurally diverse compounds known to show MDR
reversal activity are  hydrophobic and contain aromatic or
heteroaromatic rings (15-18). To find new compounds with
MDR reversal activity, ca. 150 compounds containing a carbo-
and/or heterocyclic skeleton and various functional groups,
which were prepared in recent years in the Institute of
Pharmaceutical Chemistry, University of Szeged, Hungary,
were tested for MDR reversal effect. Some derivatives of 1,2-
disubstituted tetrahydroisoquinoline containing N-
thiocarbamoyl or N-hydroxyalkyl moieties showed a remarkable
activity. Our present aim was to synthesize further analogues
for more detailed studies. To provide a wide structural diversity
in the new derivatives, both substituents at positions 1 and 2 of
the tetrahydro-isoquinoline ring were varied to a great extent.
Materials and Methods
Chemistry. Synthesis of the target compounds was performed starting
from 1-substituted-1,2,3,4-tetrahydroisoquinoline difunctional
compounds (diamine, amino acid and amino alcohol derivatives) by
using N-substitution reactions. 
Tetrahydroisoquinoline 1,2- and 1,3-diamines were prepared from
homoveratryl amine and the corresponding N-protected ·- or ‚-
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amino acid, which were coupled by using a mixed anhydride method.
Bischler-Napieralski ring-closures of carboxamides 2 and 6 resulted
in dihydroisoquinolines 3 and 7, which were reduced with sodium
borohydride to yield tetrahydroisoquinolines 4 and 9 (Figures 1 and
2) (19). The activated methylene group of compound 7 was
hydroxymethylated by treatment with paraformaldehyde in the
presence of sodium ethylate (20,21). Sodium borohydride reduction
of 8 resulted in the corresponding tetrahydro-isoquinoline 10 with a
high diastereoselectivity. The relative configuration of amino-alcohol
10 was deduced from the steric structure of its azeto[2,1-
a]isoquinoline derivative (Figure 2) (22).
The synthesis of tetrahydroisoquinoline ‚-amino acid derivatives
14 and 15 was achieved by condensation of 6,7-dimethoxy-3,4-
dihydroisoquinoline either with cyanoacetic acid or with monoethyl
malonate, respectively (23). Lithium aluminium hydride reduction
of 15 led to the corresponding amino alcohol (homocalycotomine:
16) (Figure 3) (24). 1-Methyl-substituted homocalycotomine (18)
was prepared according to the known procedure (20,21).
On reacting tetrahydroisoquinolines 4, 9, 10 and 18 with
isocyanates or isothiocyanates, the corresponding urea or thiourea
derivatives (5a-j, 11a,b and 19a,b) were formed in good yields. 
Hereby the synthesis of 5h is given as a typical procedure for the
preparation of urea or thiourea derivatives. A mixture of 1.07 g 
(3 mmol) 4 and 0.49 g (3.3 mmol) p-tolyl isothiocyanate was stirred
and refluxed in 25 ml toluene for 1 hour. The cooled mixture was
allowed to stand at ambient temperature after adding of 25 ml
Et2O. The separated crystals were filtered off, washed with Et2O
and recrystallized. The yield was 1.03 g (68%). 
On refluxing tetrahydroisoquinolines 10, 14-16 and 18 with
substituted epoxides, the corresponding (2-hydroxy-alkyl)-
substituted derivatives (12a-c, 17a-f and 20) were formed by ring-
opening reactions (Figures 1-4). 
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Figure 1. i: ClCOOEt/Et3N/toluene, ii: 2-(3,4-dimethoxyphenyl)ethylamine/CH2Cl2 (62%: i + ii), iii: POCl3/CHCl3 (71%), iv: NaBH4/MeOH (83%),
v: R1NCX/toluene (64-86%)
Figure 2. i: POCl3/CHCl3 (74%), ii: NaBH4/MeOH (78-82%), iii: (CH2O)x/NaOEt/EtOH (77%), iv: PhNCS/toluene (80-87%), v: R
3-substituted
oxirane/EtOH (72-85%).
Furthermore, the synthesis of 17a is given as a typical procedure
for the preparation of (2-hydroxy-alkyl)-substituted derivatives. A
solution of 0.70 g (3 mmol) 14 and 0.99 g (6 mmol) 3-(m-tolyloxy)-1,2-
epoxypropane in 25 ml EtOH was refluxed for 10 hours. The solvent
was evaporated off and the oily residue was converted to the
crystalline HCl salt of 17a by treatment with 20% ethanolic HCl and
Et2O. The separated crystals were filtered off, washed with a mixture
of MeOH and Et2O and recrystallized. According to the 1H NMR
spectrum, the crystalline product proved to be a ca. 1:1 mixture of
diastereomers. Ring-openings occurred on the sterically less hindered
carbon to give only regioisomers bearing substituents R at position 2.
The yield was 0.87 g (67%). According to the 1H NMR spectrum, the
crystalline product proved to be a ca. 1:1 mixture of diastereomers. 
Diastereomers of compounds 12a,b, 17a-f and 20 were not
separated before pharmacological investigations. 
Table I and Table II summarize the structures of the urea/
thiourea derivatives (5a-j, 11a,b and 19a,b) and the (2-hydroxy-
alkyl)-substituted derivatives (12a-c, 17a-f and 20), respectively. All
compounds were characterized by IR, elementary analysis and
NMR (400 Mhz). Data are available on request.
Bioassays
Cell culture. The parent MCF-7 human breast adenocarcinoma as
well as the MCF-7/Adr cell line overexpressing P-gp were a gift
from Dr. J. Carmichael (University of Nottingham, UK) and were
originally derived from the laboratory of Dr. K. Cowan (NCI,
Bethesda, MD, USA) (25,26). The MCF-7/Adr cells are >100-fold
resistant to adriamycin, vincristine and vinblastin as compared to
the parent cell line (27,28). This difference in sensitivity was
investigated and confirmed on receipt of the cells. Cells were
maintained in Eagle’s minimum essential medium with Earle’s salts
containing 2 mM L-glutamine under 5% CO2 at 37ÆC. The MCF-
7/Adr were cultured in the presence of 1 Ìg/ml adriamycin. Prior
to the use in experiments, the resistant cells were grown for at least
two passages in the absence of adriamycin.
Plasma membrane glycoprotein inhibition assay. The individual test
compounds were dissolved in DMSO (40 mM) and stored at -20ÆC.
The compounds were assayed in a fluorescence microtiter plate assay
using a standard functional assay with rhodamine (6G) as a
fluorescent probe to assess MDR activity (10,29,30). MCF7/Adr cells
were seeded in 96-well microplates (40000 cell/well). Twelve to
eighteen hours later, the test compounds were added to the cells in
the presence of rhodamine 6G (0.3 ÌM) (Sigma, St. Louis, USA) and
incubated for 3.5 hours. Verapamil (Sigma), a well-known MDR
modulating agent (28,31), was used as a positive control. After
washing three times with ice-cold phosphate-buffered saline (PBS),
the cells were dislodged with 100 Ìl phenol red-free trypsin (Gibco
BRL, UK), transferred to new 96-well microplates and solubilized in
100 Ìl 4% sodium dodecylsulphate (SDS) solution. Fluorescense due
to released rhodamine 6G was assayed at 530/590 nm
(excitation/emission) using a Biotek FL600 microplate fluorescence
reader. The amount of rhodamine 6G accumulation observed in the
presence of the individual test compounds (40 ÌM) was expressed
relative to the accumulation observed in untreated MCF7/Adr cells.
This accumulation factor (AF) was calculated as the mean of 3
independent experiments. For the compounds that displayed an AF
greater than 3.0 (approximately the AF of verapamil), concentration-
response curves were constructed and the AC50 values (concentration
of the test compound eliciting 50% of its maximal effect on
rhodamine 6G accumulation) were determined using Prism 2.01
(GraphPad Software Inc. CA, USA). ANOVA was performed to
determine whether the observed differences in the AF and the AC50
values, respectively, were statistically significant.
Antiproliferation assay. HeLa (human cervix carcinoma) cells were
seeded in 96-well microplates (5000/well). After 12-18 hours, the
test compounds were added to the cells, in concentrations ranging
from 0.25 ÌM to 80 ÌM. After 72 hours the surviving fraction was
determined with a MTT antiproliferation assay, which is based on
the ability of mitochondrial enzymes to reduce 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT)
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Figure 3. i: R4CH2COOH (ref. 14),  ii: LiAlH4/THF (ref. 15),  iii: R3-substituted oxirane/EtOH (65-92%).
Figure 4. i: R1NCS/toluene (85-91%), ii: R3-substituted oxirane/EtOH (78%)
(Sigma, Steinheim, Germany) into purple formazan crystals. For
this purpose, the medium was replaced by a 1 mg/ml MTT
solution in fresh medium, followed by incubation at 37ÆC for 3
hours. The MTT solution was then removed and replaced with
200 Ìl DMSO. The concentration of formazan per well was
determined by measuring its absorbance at 550 nm using a
microplate reader (FL600, Biotek, Winooski, VT, USA). The
surviving fractions of the cells were calculated from 3 replicates.
Concentration-response curves were constructed and the IC50
values (concentration of the test compound inhibiting 50% of cell
proliferation) were determined using Prism 2.01 (GraphPad
Software Inc.)
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Comp. R1 R2 X
5a – O
5b – O
5c – S
5d – S
5e – S
5f – S
5g – S
5h – S
Table I. Structure of the tetrahydroisoquinoline urea and thiourea derivatives.
Comp. R1 R2 X
5i – S
5j – S
5k – S
11a H S
11b –CH2OH S
19a – S
19b – S
Table II. Structure of the N-(2-hydroxyalkyl)tetrahydroisoquinoline derivatives. 
Comp.* R3 R4
12a –
12b –
17a CN
17b CN
17c CN
*Compounds 12, 17 and 20 were purified and tested as hydrochloride salts.
Comp.* R3 R4
17d CN
17e COOEt
17f CH2OH
20 –
Results
Increase in rhodamine 6G accumulation. In case of MCF7/Adr
treated with verapamil (20 ÌM) (positive control), the AF
(rhodamine 6G accumulation observed in treated relative to the
accumulation observed in untreated MCF7/Adr cells)
amounted to 3.11±0.10, while the accumulation of rhodamine
6G  in the non-resistant parent MCF7 cells was 12.5-fold higher
when compared to the resistant subline. Therefore the results
obtained with rhodamine 6G, as a compound mimicking
chemotherapeutics that are pumped out by MDR tumor cells,
are consistent with previous work where it was shown that
verapamil (10 ÌM) was able to increase the intracellular
concentration of adriamycin and vinblastine in MCF7/Adr cells
with a factor 4 and 7.5, respectively (28), and that the net
accumulation of vinblastine by sensitive MCF7 cells was
approximately 12-fold greater than MCF7-Adr cells (27). 
The influence of the synthesized molecules on the
rhodamine 6G accumulation was determined at a
concentration of 40 ÌM. The calculated AF values for all 24
compounds and verapamil are given in Table III. 
Nine compounds (5a-b, 5d, 5g, 5i, 5j, 12b, 17c, 20) were
found to have an AF greater than 3.0, which indicates that they
are at least as effective inhibitors of the P-gp as verapamil.
Consequently, their AC50 values (concentration of the
compound eliciting 50% of the maximal rhodamine 6G
accumulation) were determined from their concentration-
response curves (see Table IV). With the exception of 17c, all
compounds were found to have an AC50 significantly lower
than verapamil (p<0.001). 
Ratio IC50/AC50. To better understand their potential as safe
MDR inhibitors, the cytotoxic character of the selected
compounds was assessed by means of an antiproliferative assay.
The IC50 values (concentration of the compound inhibiting
50% of cell proliferation) are given in Table IV. Furthermore
the respective IC50/AC50 ratios were calculated (see Table IV).
The larger this ratio, the  less the compound induces a cytotoxic
effect at concentrations that are effective in inhibiting the P-gp,
reverting the MDR-phenotype of the treated malignant cells. 
Discussion
As shown by the results, 9 out of the 24 synthesized and
investigated tetrahydroisoquinoline derivatives were found
to inhibit the P-gp transport pump at least as effectively as
verapamil. In the case of 6 of them, the observed increase
in rhodamine 6G accumulation was even significantly
greater. In parallel, all selected compounds (with the
exception of compound 17c) exhibited an AC50 significantly
lower than that of verapamil. These findings suggest that, in
the case of 5 compounds that displayed AFs higher than
twice the AF value of verapamil (5a-b, 5i, 12b, 20), the
maximal inhibitory effect of verapamil could be reached by
administering a significantly lower drug concentration. 
However, this increased potency is only advantageous
when at effective concentrations the compounds are free of
side-effects such as cytotoxicity. Fortunately, from the
selected tetrahydroisoquinoline derivatives, it was compound
20 that was found to combine the highest AF (8.43±0.07)
and the lowest AC50 value (2.4±0.22 ÌM) with the highest
IC50/AC50 ratio (22) recorded. As a matter of fact, the
maximal P-gp inhibition caused by verapamil could be
reached by using 2.4 ÌM of compound 20, which is 22 times
lower than its IC50. Alternatively, 24 ÌM of verapamil only
produced half of the inhibition reached by 2.4 ÌM of
compound 20, implying that approximately a two-fold
greater P-gp inhibition could be reached at a ten-fold lower
concentration without obvious cellular side-effects. 
Further experiments will need to be carried out to verify
the P-gp inhibitory and cytotoxic effects on other resistant
cell lines of this compound. Besides acute and chronic
toxicity data, the in vivo efficacy of reverting MDR of
resistant cells should complement the present findings for
appreciation of its potential as a P-gp inhibitor.  
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Table III. Accumulation factor (AF) (rhodamine 6G accumulation observed in treated cells relative to the accumulation observed in untreated MCF7/Adr
cells) calculated for the investigated tetrahydroisoquinoline derivatives and verapamil. 
Comp. AF Comp. AF Comp. AF Comp. AF
5a 8.69±0.94*** 5g 3.73±0.28 11b 1.35±0.2 17b 0.98±0.01
5b 7.04±0.21*** 5h 1.52±0.08 19a 1.28±0.01 17c 3.08±0.09
5c 2.49±0.11 5i 8.22±0.52*** 19b 1.11±0.12 17d 1.79±0.09
5d 3.67±0.16 5j 5.69±0.57** 12a 1.45±0.08 17e 1.44±0.05
5e 2.72±0.06 5k 1.39±0.04 12b 8.21±0.5*** 17f 1.68±0.02
5f 1.73±0.05 11a 1.44±0.03 17a 1.22±0.06 20 8.43±0.07***
Verapamil 3.11±0.11
Data are given as mean±s.e.m. (n=3). (**p<0.01, ***p<0.001 significantly higher as compared to verapamil).
Table IV. The IC50 values (concentration inhibiting 50% of cell proliferation), AC50 values (concentration eliciting 50% of the maximal rhodamine 6G
accumulation) of the selected tetrahydroisoquinoline derivatives and verapamil, and the corresponding calculated  IC50/AC50 ratios. IC50 and AC50
values are given as mean±s.e.m. (*=at the highest concentration used (80 ÌM), still more than 50% cell proliferation was observed) 
Comp. IC50 AC50 Ratio Comp. IC50 AC50 Ratio
(ÌM) (ÌM) (ÌM) (ÌM)
20 52.4±7.1 2.4±0.22 22 5d > 80* 7.8±0.2 >10
5i 7.5±0.48 3.9±0.08 1.9 5j 13.3±2.8 3.8±0.4 3.5
5a 14.0±3.9 7.3±0.9 1.9 5g 7.7±0.12 8.1±0.5 0.9
12b 23.2±1.53 9.9±0.6 2.3 17c 41.8±5.5 25.0±0.7 1.7
5b > 80* 8.0±0.18 >10 verapamil > 80* 24.0±4.3 >3.3
